Table 1.
Characteristics of all patients with AML and by NCCN risk category.
| Variable | NCCN Risk Category | |||
|---|---|---|---|---|
| Total (N=508) |
Favorable (n=139) |
Intermediate (n=175) |
Poor (n=194) |
|
| Sex, n (%) | ||||
| Male | 264 (52.0) | 72 (51.8) | 92 (52.6) | 100 (51.5) |
| Female | 244 (48.0) | 67 (48.2) | 83 (47.4) | 94 (48.5) |
| Age, years | ||||
| Median | 49.0 | 50.0 | 48.0 | 48.0 |
| IQR | 40.0–55.0 | 43.0–55.0 | 40.0–55.0 | 38.0–55.0 |
| WHO Performance Status, n (%) | ||||
| 0 | 289 (58.6) | 80 (59.3) | 100 (59.2) | 109 (57.7) |
| 1 | 143 (29.0) | 43 (31.8) | 50 (29.6) | 50 (26.5) |
| 2 | 59 (12.0) | 11 (8.2) | 19 (11.2) | 29 (15.3) |
| 3 | 2 (0.4) | 1 (0.7) | 0 (0) | 1 (0.5) |
| Missing | 15 (-) | 4 (-) | 6 (-) | 5 (-) |
| Presence of comorbidities, n (%) | ||||
| No comorbidities | 402 (84.1) | 106 (80.9) | 136 (82.9) | 160 (87.4) |
| At least 1 comorbidity | 76 (15.9) | 25 (19.1) | 28 (17.1) | 23 (12.6) |
| Missing | 30 (-) | 8 (-) | 11 (-) | 11 (-) |
| Hb level, g/dL | ||||
| Median | 8.9 | 8.9 | 9.2 | 8.6 |
| IQR | 8.1–10.0 | 8.2–10.0 | 8.2–10.5 | 8.0–9.8 |
| WBC count, cells x109/L | ||||
| Median | 14 | 17.4 | 5.7 | 27.3 |
| IQR | 3.4–50.0 | 5.6–57.0 | 2.0–22.5 | 6.1–70.9 |
| Blast cells, % | ||||
| Median | 54.0 | 54.5 | 40.0 | 62.0 |
| IQR | 20.0–80.0 | 20.0–74.0 | 10.0–77.0 | 39.0–90.0 |
| Platelet count, x103/L | ||||
| Median | 55.0 | 56.0 | 55.0 | 50.0 |
| IQR | 29.0–94.0 | 28.0–94.0 | 30.0–108.0 | 28.0–82.0 |
Abbreviations. NCCN, National Comprehensive Cancer Network; IQR, interquartile range; WHO, World Health Organization; Hb, hemoglobin; WBC, white blood cell.